35.47
Hims Hers Health Inc stock is traded at $35.47, with a volume of 31.77M.
It is up +11.23% in the last 24 hours and up +59.13% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$31.89
Open:
$32.6
24h Volume:
31.77M
Relative Volume:
1.21
Market Cap:
$8.21B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
67.94
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
+22.86%
1M Performance:
+59.13%
6M Performance:
+2.01%
1Y Performance:
-41.92%
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HIMS
Hims Hers Health Inc
|
35.47 | 7.38B | 2.35B | 128.37M | 57.42M | 0.5221 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 48.72B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
8.96 | 39.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 37.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
78.71 | 32.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
536.59 | 23.41B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | JP Morgan | Overweight |
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Hims & Hers Health Inc (HIMS) Shares Surge 11.2% -- What GF Scor - GuruFocus
HIMS Shows Strong Bullish Momentum with Notable Stock Surge - GuruFocus
HIMS (NYSE) Form 144: 12,500 and 11,226 vested Class A shares listed - Stock Titan
Hims & Hers Stock Jumps After Barclays Raises Price Target - Benzinga
Hims & Hers Rallies With a July FDA Decision Looming - TradingView
HIMS Maintained by Barclays -- Price Target Raised to $39.00 - GuruFocus
Hims & Hers Health gains as investors appear to lean into growth outlook and global expansion - Quiver Quantitative
Closed all position, was too greedy aiming for highest 34.65 ended up earned a bit lesser - Moomoo
Hims & Hers: The Bull Case Remains Strong (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health: Legal Risks Resolved With New International Growth DriverMaintain Buy - Seeking Alpha
Hims & Hers Health, Inc. (HIMS) ascends while market falls: Some facts to note - MSN
Hims & Hers COO Michael Chi sells $441,850 in company stock By Investing.com - Investing.com South Africa
Hims & Hers (HIMS) CMO logs RSU vesting and tax share withholding - Stock Titan
Hims & Hers (NYSE: HIMS) CFO exercises RSUs as shares withheld for tax - Stock Titan
Hims & Hers (HIMS) exec nets shares after 32,919 RSU conversion - Stock Titan
Hims & Hers (NYSE: HIMS) COO sells 14,027 shares, holds 432,124 - Stock Titan
Hims & Hers (NYSE: HIMS) PAO trades shares under 10b5-1 plan - Stock Titan
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity - Stock Titan
Hims & Hers (NYSE: HIMS) CEO exercises RSUs and withholds shares for taxes - Stock Titan
Hims & Hers Health (HIMS) CTO exercises awards and sells 30,040 shares - Stock Titan
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note - Yahoo Finance Singapore
Hims & Hers Health (HIMS) up 15.8% since last earnings report: Can it continue? - MSN
HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership - Stocktwits
Hims Holdings (HIMS) Form 144: Director lists proposed sale of Class A shares - Stock Titan
[144] Hims & Hers Health, Inc. SEC Filing - Stock Titan
HIMS (NYSE) Form 144 shows insiders propose selling 14,027 and 97,289 Class A shares - Stock Titan
HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst - Yahoo Finance
Hims & Hers Enters A New Phase (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Inc (HIMS) Stock Up 4.3% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Hims & Hers Stands to Get a Big Chunk of the $2.2B Peptides Market - Barron's
Hims & Hers Stock Is Climbing Tuesday: What Investors Need To Know - Benzinga
Insider sells 5,529 Class A shares at HIMS (HIMS) via Fidelity - Stock Titan
Leerink reiterates Hims & Hers stock rating ahead of peptide meeting - Investing.com
HIMS Stock Logs Best Day In 2 Months: Bull Sees Peptides Driving Up To $19B In Annual Revenue By 2030 - Stocktwits
3 Market-Beating Stocks with Exciting Potential - The Globe and Mail
Hims & Hers (HIMS) Climbs 12.5% as Obesity Market Momentum Builds - Insider Monkey
Hims & Hers Shareholders Reaffirm Board, Pay, and Auditor - TipRanks
Why Hims & Hers Health (HIMS) Is Up 11.0% After GLP-1 Weight Loss Pivot And Telehealth Deal - Yahoo Finance
Hims & Hers (NYSE: HIMS) director acquires 4,613 shares via RSU grants - Stock Titan
Hims & Hers (NYSE: HIMS) director converts 3,656 RSUs into common shares - Stock Titan
Hims & Hers Health (HIMS) director exercises 3,656 RSUs into common stock - Stock Titan
Hims & Hers (NYSE: HIMS) CMO exercises 4,091 RSUs, holds 187,971 shares - Stock Titan
Executive at Hims & Hers (HIMS) receives 3,656 shares from RSU vesting - Stock Titan
Hims & Hers (NYSE: HIMS) director Amoo-Gottfried Kofi Owusu files initial Form 3 - Stock Titan
Hims & Hers (NYSE: HIMS) director exercises RSUs for 14,343 shares - Stock Titan
Hims & Hers (HIMS) director gains 3,656 shares via RSU exercise - Stock Titan
Director at Hims & Hers (NYSE: HIMS) gains 13,696 shares through RSU exercises - Stock Titan
Hims & Hers (HIMS) director exercises 3,656 RSUs into Class A shares - Stock Titan
[8-K] Hims & Hers Health, Inc. Reports Material Event - Stock Titan
(HIMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
HIMS Stock Set To Test A Crucial Resistance – Is Retail Expecting A Breakout? - Yahoo Finance
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):